<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28365">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842516</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-12-1-02</org_study_id>
    <nct_id>NCT01842516</nct_id>
  </id_info>
  <brief_title>Multiple Ascendoing Dose Study for LCB01-0371</brief_title>
  <official_title>A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCB01-0371 in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary

      - To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose

        -  To investigate the pharmacokinetic characteristics of LCB01-0371 after a multiple oral
           dose

        -  To investigate the safety of LCB01-0371 after a multiple oral dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To investigate the PK characteristics of LCB01-0371 after a multiple oral dose

        -  To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of LCB01-0371</measure>
    <time_frame>Up to 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of LCB01-0371</measure>
    <time_frame>Up to 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371  800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCB01-0371 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 1200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg</intervention_name>
    <description>LCB0-0371 800mg</description>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <other_name>LCB0-0371 800mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 1200mg</intervention_name>
    <description>LCB01-0371 1200mg</description>
    <arm_group_label>LCB01-0371 1200mg</arm_group_label>
    <other_name>LCB01-0371 1200mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Health Male between 20 and 45 years of age at the time of screening and a subject
             with body mass index (BMI) between 19 and 27

          2. Medically healthy with no clinically significant screening results through Physical
             examination, x-ray, 12 lead ECG, Laboratory test

          3. Able to donate blood during study period and follow visit.

          4. Agree to continue to use a reliable method of birth control until 60 days after study
             completion.

          5. Capable of giving written informed consent and Able to understand and comply with
             protocol requirements, instructions and protocol-stated restrictions.

        Exclusion Criteria:

          1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic,
             neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).

          2. History of gastrointestinal problem which is affect to absorption within 6 months
             from screening

          3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the
             LCB01-0371, same class of the study drugs (linezolid), or other drugs including
             aspirin and antibiotics.

          4. History drug abuse or positive result of urine drug screening test for amphetamine,
             methamphetamine, barbiturate, cocaine, opiate, benzodiazepine, cannabinoid,
             methadone, etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyun-Seop Bae, , MD, PhD.</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <phone>82-2-3010-4611</phone>
      <email>ksbae@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 24, 2013</lastchanged_date>
  <firstreceived_date>April 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
